Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
ChinaBio® Today
www.ChinaBioToday.com
ChinaBio® Today is the most widely-read source for China life science news and analysis. From our offices in Shanghai and California, we provide daily news, commentary and analysis on public and private China life science companies and industry events, as well as global issues affecting the China life science industry.

News

< Previous 1 2 3 Next >
Sinovent Completes Pre-IPO Financing of at least $30 Million
Suzhou Sinovent completed a pre-IPO financing of at least $30 million in a round led by Oceanpine Healthcare Fund. Founded in 2016, Sinovent is a global biopharma that has 12 biologic products in... 
Neurophth to Develop AAV Capsids with AAVnerGene for Ophthalmology
Neurophth Therapeutics of Wuhan partnered with Delaware 's AAVnerGene to develop adeno-associated virus (AAV) capsids for next-gen ophthalmic gene therapies. Neurophth will make an initial cash payment... 
Tickers AAV
Gracell to Start China Trial of CAR-T in Leukemia Patients
Suzhou 's Gracell Biotech will start a China trial of its FasTCAR cell therapy in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia (B-ALL). GC019F modifies a patient's own... 
Tickers GRCL
EdiGene Approved to Start China Trial of Gene-Edited Stem Cell Therapy
EdiGene, a Beijing company, was approved to start China clinical trials of ET-01, its gene-edited stem cell therapy, to treat transfusion dependent β-thalassemia. Thalassemia is a group of blood... 
TenNor and Janssen to Collaborate on Lung Disease Treatments
TenNor Therapeutics ( Suzhou ), a company that develops dual-action antibiotics, announced a research collaboration with Janssen Pharma that will use TenNor's drug conjugation platform to discover new... 
Tickers NTM
TenNor and Janssen to Collaborate on Lung Disease Treatments
TenNor Therapeutics ( Suzhou ) announced a research collaboration with Janssen Pharma that will use TenNor's drug conjugation platform to discover new therapies for the treatment of nontuberculous... 
Tickers NTM
Week in Review: BeiGene Signs $2.2 Billion Deal with Novartis for PD-1
Deals and Financings   Beijing 's BeiGene out-licensed ex-China rights for its China-approved anti-PD-1 antibody to Novartis in a $2.2 billion agreement, including a $650 million upfront payment;... 
Tickers GRCL
EQRx Raises $500 Million to Develop China-Sourced Drugs for US Market
EQRx, a Cambridge , MA biopharma that aims to lower US drug prices for expensive medications by 50%-70%, completed a $500 million Series B funding. Three of EQRx's four drug candidates are from China... 
Raysight Completes $46 Million Funding for Cardiovascular Diagnosis
Shenzhen Raysight Medical completed a $46 million Series B funding for its smart systems that offer real-time monitoring to provide early warnings of heart disease. Raysight said it would use the... 
ChinaBio® Report: 2020 China Life Science Investment Hits New Records
In 2020, investment in China life science showed stellar growth. ChinaBio®'s survey  shows four of the five investment categories set new records, often doubling the year-earlier comparison, while the... 
CICC Has Second Close of Biomedical Fund at $648 Million
CICC Capital announced its RMB biomedical private equity fund, called CICC Qide, has raised $648 million as of the second closing. In February of 2020, CICC announced the first close with $247 million.... 
Henlius In-licenses TPOR-2 mAbs from Chiome in $122.5 Million Deal
Shanghai Henlius Biotech announced a $122.5 million agreement to acquire greater China rights for two anti-TPOR-2 antibodies from Chiome Bioscience of Japan . As part of the package, Henlius has an... 
Gracell to Start China Trial of Donor-derived CAR-T Therapy for B-ALL
Gracell Biotech, a Suzhhou company developing novel CAR-T therapies, was approved to start a China Phase I/II clinical trial of its allogeneic donor-derived CD19 CAR-T cell therapy. GC007g will be... 
Tickers GRCL
BeiGene Out-Licenses Rights for PD-1 to Novartis in $2.2 Billion Deal
Beijing 's BeiGene out-licensed ex-China rights for tislelizumab, its China-approved anti-PD-1 antibody, to Novartis in a $2.2 billion agreement. The blockbuster deal includes a $650 million upfront... 
Visen Pharma Closes $150 Million Financing for Endocrine Drugs
Shanghai 's Visen Pharma closed a $150 million Series B financing to develop novel endocrine drugs in a round led by Sequoia China . In 2018, Visen was formed by Ascendis Pharma A/S of Denmark and an... 
Tickers ASND
ChinaBio at JP Morgan: China Biopharma Books Strong 2020, Despite Pandemic
China 's biopharma industry continued to grow at a rapid pace in 2020, in spite of the formidable obstacle presented by COVID-19. Panelists at the China Showcase, a virtual event preceding the JP... 
Inmagene Signs $920 Million Agreement to Acquire Four Chi-Med Immunology Therapies
Shanghai 's Inmagene in-licensed global rights to four novel pre-clinical immunological candidates from Hutchison China MediTech (Chi-Med) in a deal that has a potential value of $920 million. With... 
BeiGene Acquires Rights to mRNA Cancer Therapy in $320 Million Deal
Beijing 's BeiGene announced a $310 million agreement for China/Asia rights to an mRNA treatment developed by Strand Therapeutics for solid tumor cancers. Strand, a Cambridge , MA biotech, focuses on... 
EOC Signs $271 Million Agreement for mTor Inhibitor from Aadi Bio
EOC Pharma, the Shanghai oncology arm of China company Eddingpharm, acquired greater China rights to an mTOR inhibitor from Los Angeles-based Aadi Bioscience. EOC signed a $271 million agreement... 
Week in Review: China Biopharma Starts 2021 with Over $1 Billion in Deals and IPOs
Deals and Financings   Gracell Biotech of Suzhou raised $209 million in a US IPO for its next-gen CAR-T treatments, which can be manufactured in one day or are off-the-shelf products; APT Medical... 
Tickers EYPT GILD GRCL INO
Gracell Raises $209 Million in US IPO for Novel CAR-T Therapies
Gracell Biotech of Suzhou completed a $209 million NASDAQ IPO for its next-get CAR-T treatments. Gracell set out to address the difficulties presented by previous cell therapies, including complex... 
Tickers GRCL
Abbisko Announces $123 Million Financing for Cancer Portfolio
Abbisko Therapeutics of Shanghai completed a $123 million Series D financing to develop its portfolio of 12 oncology and one diabetes candidates that it hopes will be best-in-class treatments. The... 
Abbisko Announces $123 Million Financing for Cancer Portfolio
Abbisko Therapeutics of Shanghai completed a $123 million Series D financing to develop its portfolio of 12 oncology and one diabetes candidates that it hopes will be best-in-class treatments. The... 
Zai Lab Acquires China Rights to Novel Autoimmune Drug in $175 Million Deal
Shanghai 's Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up to $175 million in upfront and near-term payments. argenex's efgartigimod... 
APT Medical Closes $191 Million Shanghai STAR Board IPO
APT Medical completed a $191 million IPO on the Shanghai STAR Exchange, rising 245% in its first trading session to a market cap of $2.7 billion. Founded in 2002, the company makes a variety of... 
Kira Closes $53.5 Million B+ Round for Complement-Targeted Drugs
Kira Pharma closed a $53.5 million Series B+ financing to develop complement-targeted therapies that treat immune-mediated diseases. Kira is headquartered in Cambridge , MA with R&D operations in... 
Keya Medical Completes $46 Million Round for AI-based Scanning Software
Keya Medical completed a $46 million D financing in late December to support its automated scanning products based on deep learning algorithms. It was the company's fourth funding in 2020 that included... 
Everest to Start China Phase III Trial of ADC For Urothelial Cancer
Everest Medicines was approved to start a China Phase III trial of sacituzumab govitecan-hziy in patients with metastatic urothelial cancer. The candidate is a first-in-class, antibody-drug conjugate... 
Tickers ADC GILD
Terns Completes $87 Million Financing to Advance Three NASH Candidates
Terns Pharma, a San Mateo-Shanghai biopharma, completed a $87 million Series C round to support its three lead NASH programs. The financing was led by Deerfield Management Company and included a... 
Paratek Closes $60 Million Loan Using Zai Lab Royalties for Pay Off
Boston's Paratek Pharma closed a $60 million non-recourse loan with an affiliate of R-Bridge Healthcare that will be paid off by royalties from Paratek's China omadacycline out-licensing agreement with... 
Tickers PRTK
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.